胃癌是全球的重大健康负担。它是全球第二大常见的癌症死因，是赞比亚癌症死亡的第九位主要原因，死亡率为每10万人口3.8人次；与美国（每10万人口2人次）和英国（每10万人口3.4人次）相当。赞比亚关于胃恶性肿瘤的生存数据尚不清楚。我们使用我们的前瞻性胃癌研究数据库，对赞比亚大学教学医院自2010年6月至2012年1月期间被诊断为胃癌的病人进行了回顾性审查。我们通过提供的电话号码与患者或其亲属取得联系。我们审查了年龄、性别、人口统计数据（收入、教育）、身体质量指数、症状、症状持续时间、治疗（手术、化疗、放疗或联合治疗）和生存结果。使用Kaplan-Meier模型和对数秩和检验进行了分析。在研究期间，诊断为胃腺癌的患者有51例，但50例患者有随访数据。生存中位数为142天。年龄、性别、收入、教育、BMI、肿瘤位置和治疗模式与总生存率无显著关联。Cox回归模型中，与生存相关的协变量是定期饮酒史（HR 0.49，95%CI 0.26,0.92；P=0.025）和肠型癌组织学（HR 0.40，95%CI 0.19,0.83；P=0.01）。赞比亚新诊断的胃癌预后很差，诊断后1年内有显著的死亡率，尤其是那些有体重减轻和吞咽困难的患者。

Gastric cancer poses a significant global health burden. It is the second most common cause of cancer death worldwide and the ninth leading cause of cancer mortality in Zambia, at a rate of 3.8/100,000; comparable to USA (2/100,000) and UK (3.4/100,000). Survival data on gastric malignancy in Zambia is not known.To provide preliminary survival rates of patients with histologically proven gastric adenocarcinoma in Zambia.Using our prospective gastric cancer research database, we conducted a retrospective audit of patients diagnosed with gastric cancer at the University Teaching Hospital, Zambia, from June 2010 until January 2012. We contacted patients or their relatives using phone numbers provided at time of enrollment.We reviewed age, sex, demographic data (income, education), body mass index, symptoms, duration of symptoms, treatment (surgery, chemotherapy, radiotherapy or combination) and survival outcome. Analysis was performed using Kaplan-Meier models and log rank test.Fifty one patients were diagnosed with gastric adenocarcinoma during the study period, but follow-up data were available for 50. Median survival was 142 days. Age, sex, income, education, BMI, tumor location, and treatment modality were not significantly associated with overall survival. In Cox regression models, covariates associated with survival were a history of regular alcohol intake (HR 0.49, 95%CI 0.26,0.92; P=0.025) and intestinal type cancer histology (HR 0.40, 95%CI 0.19,0.83; P=0.01).Prognosis of newly diagnosed gastric cancer in Zambia is poor with significant mortality within 1 year of diagnosis, particularly among patients with weight loss and dysphagia.